Mode
Text Size
Log in / Sign up

Systematic Review and Meta-Analysis Links α-Klotho to Frailty and Bone Health in AgingHigher Alpha-Klotho Levels Mean Less Frailty And Better Bones

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider α-Klotho as a potential biomarker for frailty and bone health, but causality remains unestablished.

This systematic review and meta-analysis of 109 studies examined the association between circulating α-Klotho levels and aging-related outcomes, including frailty, osteoporosis, osteopenia, and physical function. The analysis also evaluated the effects of exercise interventions and habitual physical activity on α-Klotho levels.

Higher circulating α-Klotho levels were significantly associated with lower odds of frailty (OR = 0.61; 95% CI: 0.49, 0.77; p < 0.0001). Exercise interventions significantly increased α-Klotho levels (95% CI: 93.93, 261.73; p < 0.0001), while habitual physical activity showed no significant effect compared to inactive controls (p = 0.25). Individuals with osteoporosis and osteopenia had significantly lower α-Klotho levels than those with normal bone mineral density (osteoporosis: 95% CI: -114.98, -25.49; p = 0.002; osteopenia: 95% CI: -123.22, -0.74; p = 0.05). α-Klotho levels were also associated with fractures.

The authors note substantial heterogeneity across studies and the observational nature of most included research, precluding causal conclusions. Evidence for cognitive outcomes remains limited and inconsistent. They call for more standardized and longitudinal research.

Clinically, circulating α-Klotho appears to be a promising biomarker for frailty, physical function, and bone health in aging, but causality is not established. These findings should be interpreted cautiously given the limitations.

Imagine an older adult who feels strong and independent. Now picture that same person feeling weak and struggling with daily tasks. This shift is called frailty. It is a scary reality for many seniors.

New research offers a potential sign of health. Scientists found a specific protein called Alpha-Klotho. High levels of this protein seem to protect against frailty.

The Protein That Guards Against Weakness

Frailty is not just about getting older. It is a state of vulnerability. It makes people more likely to fall or get sick. Current treatments often focus on managing symptoms. They do not always fix the root cause.

This new study changes that view. It looks at a single protein. Alpha-Klotho acts like a shield for the body. It helps cells function better as we age.

Think of your cells as a factory. Alpha-Klotho is the manager who keeps the machines running smoothly. Without this manager, the factory slows down. The body loses muscle and bone strength.

What The Data Reveals

Researchers analyzed over one hundred studies. They looked at thousands of patients. The results were clear and positive.

People with higher Alpha-Klotho levels had much lower odds of frailty. The math shows a strong link. The odds dropped by nearly forty percent. This is a huge difference for patient care.

The study also looked at exercise. Working out increases Alpha-Klotho levels significantly. This is great news for anyone who wants to stay active. However, just walking every day did not show the same boost.

A Warning For Bone Health

The findings extend beyond muscle strength. Bone health is another critical area. People with low Alpha-Klotho levels had lower bone density. This condition is known as osteoporosis.

Low levels were also linked to osteopenia. This is a thinner bone state. The risk of fractures goes up when this protein is low. Fractures can be life-changing for older adults. They lead to loss of independence quickly.

This doesn't mean this treatment is available yet.

The study highlights a gap in our knowledge. We know the protein helps the body. We do not yet have a drug to boost it safely. This is why research is so important.

The Study Snapshot

The team used a strict method to find data. They searched major medical databases. They included only high-quality studies. A total of one hundred nine studies qualified.

They used advanced statistical models. This ensured the results were reliable. The analysis covered many outcomes. Grip strength and walking speed were key measures.

The results were mixed for walking tests. Some people walked faster with high levels. Others did not show a change. Grip strength and standing up from a chair improved consistently.

What Experts Say

The researchers noted some uncertainty. Most studies were observational. This means they watched people rather than testing them directly. They called for more longitudinal research. Long-term studies track patients over years.

They also noted heterogeneity. This is a fancy word for variation. Different studies had different results. Standardizing how we measure this protein is the next step.

You can talk to your doctor about your bone health. Ask if you are at risk for fractures. Regular exercise is a proven way to help. It boosts your natural Alpha-Klotho levels.

Do not wait for a new drug. Start moving today. Strength training and walking are powerful tools. They support your bones and muscles.

More trials are needed. Scientists want to create safe ways to boost this protein. They hope to turn this biomarker into a treatment. This could change how we care for aging patients.

The path is clear but long. It takes time to develop new medicines. Patience is key for patients and doctors alike. The goal is a healthier future for everyone.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Although α-Klotho has gained attention as a promising biomarker of aging, its association with frailty and broader aging-related outcomes beyond chronic kidney disease-mineral and bone disorder remains incompletely characterized. This systematic review and meta-analysis aimed to investigate the association between circulating α-Klotho levels and aging-related outcomes, including frailty, effects of physical activity and exercise interventions, body composition, cognitive and neuropsychiatric status, sarcopenia, and bone mineral density (BMD). A comprehensive literature search was performed across multiple electronic databases, including Ovid MEDLINE, Web of Science, Scopus, PubMed, and the Cochrane Library, to identify relevant studies published up to April 30, 2025. Pooled analyses were conducted using random-effects models, with effect estimates synthesized as mean differences, odds ratios, or correlation coefficients, and heterogeneity assessed using the I statistic. Risk of bias was assessed using design-specific tools, including the Newcastle-Ottawa Scale, the Risk of Bias 2 tool (RoB2) of the Cochrane collaboration, and the Joanna Briggs Institute (JBI) checklists. A total of 109 studies met the inclusion criteria and were included. In our meta-analysis, higher circulating α-Klotho levels were significantly associated with lower odds of frailty (OR = 0.61, 95% CI: 0.49, 0.77; p < 0.0001, I = 0%). Exercise interventions increased circulating α-Klotho (95% CI: 93.93, 261.73, p < 0.0001; I = 89%), but habitual physical activity showed no significant effect on α-Klotho compared to inactive controls (p = 0.25; I = 100%). Lower circulating α-Klotho levels were observed in individuals with osteoporosis compared with those with normal BMD (95% CI: - 114.98, - 25.49; p = 0.002) and in individuals with osteopenia compared with those with normal BMD (95% CI: - 123.22, - 0.74; p = 0.05), and were associated with fractures. Based on qualitative synthesis, circulating α-Klotho levels were positively associated with multiple physical function outcomes, including grip strength, short physical performance battery scores, and sit-to-stand performance, with mixed findings for gait speed and the 6-min walk test. Circulating α-Klotho appears to be a promising biomarker for frailty, physical function, and bone health in aging; however, evidence for cognitive outcomes remains limited and inconsistent. Substantial heterogeneity and the observational nature of most studies highlight the need for more standardized and longitudinal research.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.